Results 21 to 30 of about 2,693 (166)

Molecular Basis of Class A β-Lactamase Inhibition by Relebactam [PDF]

Antimicrobial Agents and Chemotherapy, 2019
β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) producers, especially strains carrying the widely disseminated class A enzymes, are required.
Catherine L. Tooke, Philip Hinchliffe, Pauline A. Lang, Adrian J. Mulholland, Jürgen Brem, Christopher J. Schofield, James Spencer   +6 more
openaire   +5 more sources

In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017

Journal of Global Antimicrobial Resistance, 2020
Objectives: Antimicrobial resistance, including multidrug-resistance (MDR), is increasing, especially among Gram-negative bacilli. New agents are needed to treat infections caused by these pathogens.
James A. Karlowsky, Sibylle H. Lob, Krystyna M. Kazmierczak, Katherine Young, Mary R. Motyl, Daniel F. Sahm   +5 more
doaj   +1 more source

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020

BMC Microbiology, 2023
Background Carbapenem-resistant bacteria are an increasing problem in clinical practice; thus, it is important to identify β-lactamase inhibitors (e.g., relebactam) that can restore carbapenem susceptibility.
David W. Hilbert, C. Andrew DeRyke, Mary Motyl, Meredith Hackel, Katherine Young   +4 more
doaj   +1 more source

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus [PDF]

Scientific Reports, 2020
AbstractInfections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic interventions. Here we report a prospective advance in the treatment of M.
Rose C. Lopeman, James Harrison, Daniel L. Rathbone, Maya Desai, Peter A. Lambert, Jonathan A. G. Cox   +5 more
openaire   +3 more sources

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Predicting the Effects of Carbapenem/Carbapenemase Inhibitor Combinations against KPC-Producing Klebsiella pneumoniae in Time-Kill Experiments: Alternative versus Traditional Approaches to MIC Determination

Antibiotics, 2021
Traditionally, the antibacterial activity of β-lactam antibiotics in the presence of β-lactamase inhibitors is determined at the fixed inhibitor concentration.
Alla V. Filimonova, Maria V. Golikova, Elena N. Strukova, Yury A. Portnoy, Anastasiya A. Kuznetsova, Stephen H. Zinner   +5 more
doaj   +1 more source

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases [PDF]

Journal of Antimicrobial Chemotherapy, 2020
Abstract Background ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via loss of OprD, isolates producing ESBLs are ...
Shazad Mushtaq, Danièle Meunier, Anna Vickers, Neil Woodford, David M Livermore   +4 more
openaire   +3 more sources

Pharmacodynamics of Doripenem Alone and in Combination with Relebactam in an In Vitro Hollow-Fiber Dynamic Model: Emergence of Resistance of Carbapenemase-Producing Klebsiella pneumoniae and the Inoculum Effect

Antibiotics, 2023
The emergence of bacteria resistant to beta-lactam/beta-lactamase inhibitor combinations is insufficiently studied, wherein the role of the inoculum effect (IE) in decreased efficacy is unclear.
Elena N. Strukova, Maria V. Golikova, Svetlana A. Dovzhenko, Mikhail B. Kobrin, Stephen H. Zinner   +4 more
doaj   +1 more source

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas -derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa .
Melissa D, Barnes, Christopher R, Bethel, Jim, Alsop, Scott A, Becka, Joseph D, Rutter, Krisztina M, Papp-Wallace, Robert A, Bonomo   +6 more
openaire   +2 more sources